Multiple CNS Therapies Advancing
An advanced pipeline that’s closer to where you live than you might expect.
cvn424
(Adjunctive & monotherapy)
cvn766
(Negative and cognitive symptoms)
CVN293
(Disease modification)
CVN398
(Disease modification)
Target-18
(Disease modification)
Target-26
(Disease modification)
Multiple Early Targets
.svg)
The CVN424/GPR6 relationship uniquely limits collateral impact to surrounding genes.
45% Increase in OFF time efficacy and up to 150% reduction in common side effect compared to current treatment options.
Target:
GPR6 - an inverse agonist for parkinson’s disease
Study Focus:
GPR6 - an inverse agonist for parkinson’s disease
Highlight:
GPR6 - an inverse agonist for parkinson’s disease
Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl e side effects. CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform. GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.
Learn moreThe CVN424/GPR6 relationship uniquely limits collateral impact to surrounding genes.
45% Increase in OFF time efficacy and up to 150% reduction in common side effect compared to current treatment options.
Target:
GPR6 - an inverse agonist for parkinson’s disease
Study Focus:
GPR6 - an inverse agonist for parkinson’s disease
Highlight:
GPR6 - an inverse agonist for parkinson’s disease
Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl e side effects. CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform. GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.
Learn moreThe CVN424/GPR6 relationship uniquely limits collateral impact to surrounding genes.
45% Increase in OFF time efficacy and up to 150% reduction in common side effect compared to current treatment options.
Target:
GPR6 - an inverse agonist for parkinson’s disease
Study Focus:
GPR6 - an inverse agonist for parkinson’s disease
Highlight:
GPR6 - an inverse agonist for parkinson’s disease
Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl e side effects. CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform. GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.
Learn moreThe CVN424/GPR6 relationship uniquely limits collateral impact to surrounding genes.
45% Increase in OFF time efficacy and up to 150% reduction in common side effect compared to current treatment options.
Target:
GPR6 - an inverse agonist for parkinson’s disease
Study Focus:
GPR6 - an inverse agonist for parkinson’s disease
Highlight:
GPR6 - an inverse agonist for parkinson’s disease
Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl e side effects. CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform. GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.
Learn moreThe CVN424/GPR6 relationship uniquely limits collateral impact to surrounding genes.
45% Increase in OFF time efficacy and up to 150% reduction in common side effect compared to current treatment options.
Target:
GPR6 - an inverse agonist for parkinson’s disease
Study Focus:
GPR6 - an inverse agonist for parkinson’s disease
Highlight:
GPR6 - an inverse agonist for parkinson’s disease
Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl e side effects. CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform. GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.
Learn more.webp)
CVN424
Target:
GPR6
Study Focus:
Parkinson’s disease
Highlight:
Significant reduction (1.5 hours) in OFF time versus placebo without dopaminergic side effects
CVN424 is a first-in-class non-dopamine therapy that selectively modulates GPR6, an orphan G-protein coupled receptor. Expression of GPR6 is largely confined to the subset of striatal projection neurons that give rise to the indirect (striatopallidal) pathway, important in the control of movement. CVN424 shows promise in improving both motor and quality of life/non-motor symptoms of Parkinson's disease and may also have disease-delaying effects.
Learn moreCVN766
Target:
Orexin 1 receptor
Study Focus:
Psychiatric conditions
Highlight:
Safe and well tolerated with no signs of somnolence
CVN766 is a potent and highly selective antagonist of the Ox1R compared to Ox2R (>1000 fold). Ox1R has genetic links to domains of psychiatric disorders and is expressed in areas of the brain important for regulating emotions, fear, anxiety and motivation. CVN766 has demonstrated efficacy in multiple preclinical models and may benefit a variety of psychiatric conditions including schizophrenia, anxiety/panic, binge eating/obesity, substance use disorder, and Prader-Willi Syndrome.
Learn moreCVN293
Target:
KCNK13
Study Focus:
ALS/Alzheimer's disease
Highlight:
Lower peripheral expression allows targeting CNS inflammation while sparing peripheral immune system
CVN293 targets KCNK13, a microglia specifically expressed potassium channel. KCNK13 inhibition will reduce K+ efflux and inflammasome formation in microglia, attenuate aberrant neuroinflammation and slow neurodegeneration. Cereveance will initiate a Phase 1 study to demonstrate safety and tolerability.
CVN398
Target:
GPR6 - an inverse agonist for parkinson’s disease
Study Focus:
GPR6 - an inverse agonist for parkinson’s disease
Highlight:
GPR6 - an inverse agonist for parkinson’s disease
Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl e side effects. CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform. GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.
Learn moreCVN424
Target:
GPR6 - an inverse agonist for parkinson’s disease
Study Focus:
GPR6 - an inverse agonist for parkinson’s disease
Highlight:
GPR6 - an inverse agonist for parkinson’s disease
Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl e side effects. CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform. GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.
Learn morePatient Resources:
We encourage connecting with organizations that focus on CNS diseases. Below you’ll find learning opportunities, ideas on ways to care for and support those with diseases caused by CNS disorders as well as how to become a part of important research.
Current
September 19, 2023
Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease
Cerevance today announced that the first subject has been dosed in the Phase 1 clinical study evaluating the safety, tolerability, and pharmacokinetics of CVN293.
August 28, 2023
Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023
Cerevance has been named by Fierce Biotech as one of the most promising early-stage biotechnology companies in the industry in 2023, showcased on this year’s Fierce 15 list.
July 10, 2023
Cerevance to Present at the Alzheimers Association International Conference
Cerevance today announced plans to present a poster presentation at the upcoming Alzheimer’s Association International Conference (AAIC), taking place in Amsterdam, Netherlands, July 16 – 20, 2023.
June 28, 2023
Cerevance to Present at the XVI European Meeting on Glial Cells in Health and Disease
Cerevance today announced plans to present a poster presentation at the upcoming XVI European Meeting on Glial Cells in Health and Disease, taking place in Berlin, Germany, July 8 – July 11, 2023.
June 26, 2023
Cerevance to Present at the Gordon Research Conference: Amyotrophic Lateral Sclerosis and Related Motor Neuron Diseases
Cerevance today announced plans to present a poster presentation at the upcoming Gordon Research Conference: Amyotrophic Lateral Sclerosis (ALS) andRelated Motor Neuron Diseases, taking place in Les Diablerets, VD, Switzerland,July 2 – July 7, 2023.
May 16, 2023
Oral Presentation of Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)
Cerevance today announced plans to present an oral presentation at the upcomingAmerican Society of Clinical Psychopharmacology (ASCP) conference, taking place in Miami, Florida, May 30 – June 2, 2023.
May 9, 2023
Cerevance to Present at Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development
Cerevance today announced plans to present at the upcoming Neurodegeneration: New Biology Guiding the NextGeneration of Therapeutic Development conference, taking place in British Columbia,Canada, May 15 – 19, 2023.
May 8, 2023
Cerevance to Present at the 2023 RBC Capital Markets Global Healthcare Conference
Cerevance today announced that Craig Thompson, chief executive officer of Cerevance, will present at the upcoming 2023 RBC Capital Markets Global Healthcare Conference being held May 16-17, 2023. Company management will also be available for virtual one-on-one meetings.
April 13, 2023
Poster Presentation at the BNA International Festival of Neuroscience
Cerevance today announced a poster presentation at the British Neuroscience Association (BNA) 2023 International Festival of Neuroscience in Brighton, United Kingdom being held April 23-26, 2023
April 10, 2023
Cerevance to Present at the Needham Healthcare Conference
Cerevance today announced that Craig Thompson, chief executive officer of Cerevance, will present at the upcoming 22nd Annual Needham Healthcare Conference.
March 27, 2023
Cerevance to Participate in Chief Medical Officer Summit 360˚
Cerevance announced that Ottavio V. Vitolo, M.D., chief medical officer of Cerevance, will participate in a roundtable discussion at the upcoming Chief Medical Officer Summit 360˚ (CMO Summit 360˚).
March 21, 2023
Cerevance to Present at Two Medicinal Chemistry Conferences
Cerevance today announced plans to present at the Alzheimer’s Research UK Conference 2023, held in Aberdeen, Scotland and virtually from March 14-15, 2023.
March 20, 2023
Cerevance to Present at AD/PD™ 2023 International Conference
- Positive CVN424 Phase 2 data for Parkinson’s disease to be presented
- Presentation of NETSseq platform’s ability to reveal novel targets to inform CNS drug development
- Novel target, CVN417, for the potential treatment of Parkinson’s disease to be disclosed
March 7, 2023
Cerevance to present at the Alzheimer’s Research UK Conference 2023
Cerevance today announced plans to present at the Alzheimer’s Research UK Conference 2023, held in Aberdeen, Scotland and virtually from March 14-15, 2023.
February 13, 2023
Cerevance Expands Series B Financing with Additional $51 Million
- Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform
- CVN424 for Parkinson’s disease will advance to Phase 2 monotherapy study in Q2 2023
- CVN766 for negative and cognitive symptoms of schizophrenia will advance to Phase 2 study in Q4 2023
- CVN293 for Amyotrophic Lateral Sclerosis will advance to Phase 1 study in Q3 2023
January 27, 2023
Cerevance Announces Publication in Organic Process Research and Development
Cerevance today announced the publication in Organic Process Research and Development entitled, “Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor”.
January 24, 2023
Cerevance to Participate at the SVB Global Biopharma Conference
Cerevance, today announced that Craig Thompson, chief executive officer of Cerevance, will participate in the upcoming SVB Global Biopharma Conference.
January 9, 2023
Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia
- CVN766 was well tolerated with no serious adverse events
- CVN766, which has >1000-fold selectivity for the orexin 1 receptor, was well tolerated and showed no evidence of somnolence
- Data supports once a day dosing of CVN766 in future studies
December 7, 2022
Cerevance to Present at the RBC Capital Markets Virtual Healthcare Private Company Conference
Craig Thompson, chief executive officer of Cerevance, will present at the upcoming RBC Capital Markets Virtual Healthcare Private Company Conference being held virtually December 14-15, 2022.
November 30, 2022
Cerevance to Present Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases – Biology and Therapeutics Conference and Publication in Neuropharmacology
- Presentation highlights a novel target identified for Alzheimer’s disease using Cerevance’s proprietary NETSseq platform
- Cerevance’s THIK-1 targeting inhibitor, C101248, demonstrated positive results in human and mouse cell based and electrophysiology assays relevant to neuroinflammation in neurodegenerative disease
- Data has been concurrently published in the peer-reviewed journal, Neuropharmacology
August 9, 2022
Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease
Cerevance today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform.
June 16, 2022
Cerevance to Present During the 5th Annual LSX World Congress USA
Carrie Cook, chief business officer (CBO) of Cerevance, will participate in a fireside chat during the 5th Annual LSX World Congress USA being held in Boston, MA, June 21-22.
June 8, 2022
Cerevance to Participate in Panel Discussion During the 2022 BIO International Convention
Craig Thompson, chief executive officer of Cerevance, will participate in a panel discussion during the 2022 BIO International Convention being held in San Diego, CA, June 13-16.
April 19, 2022
Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases
Cerevance today announced the appointment of Craig Thompson to chief executive officer. Mr. Thompson brings over 25 years of commercial and marketing leadership experience in the biotech and pharmaceutical industries to the company.
March 31, 2022
Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism
Cerevance today announced the completion of its Phase 2 clinical trial of CVN424, the company’s first-in-class, once-a-day, orally-delivered compound in development for the treatment of Parkinson’s disease.
January 25, 2022
Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766
Cerevance today announced the dosing of the first human subjects in a Phase 1 clinical trial of its compound, CVN766.
September 8, 2021
Neuroscience Drug Development Veteran Mike Poole, M.D., FACP, to Join Cerevance Board of Directors
Cerevance today announced the appointment of Mike Poole, M.D., FACP, to Cerevance’s Board of Directors.
February 10, 2021
Cerevance Appoints Naidong Ye, Ph.D. as Vice President and Head of Chemistry, Manufacturing and Controls
Cerevance today announced the appointment of Naidong Ye, Ph.D., a seasoned chemist with extensive pharmaceutical industry experience, as vice president and head of chemistry, manufacturing and controls (CMC).
February 1, 2021
Cerevance Appoints Carrie Ann Cook as Chief Business Officer
Cerevance, today announced the appointment of Carrie Ann Cook, a global business development executive with more than 20 years of experience in the pharmaceutical industry, as chief business officer
December 8, 2020
Cerevance Appoints David Lubner to Board of Directors
Cerevance today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Cerevance’s Board of Directors.
November 16, 2020
Cerevance’s CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study
Cerevance today announced positive results from a Phase 1b clinical trial evaluating the company’s oral compound, CVN058, in a biomarker study evaluating its potential as a treatment for cognitive impairment associated with schizophrenia (CIAS).
July 21, 2020
Cerevance Expands Series B Financing to $65 Million
Cerevance, a private drug discovery and development company focused on brain diseases, has expanded its Series B financing round, adding $20 million to the $45 million that it announced in April.
April 14, 2020
Cerevance Closes $45 Million Series B Financing
Cerevance has closed a Series B financing, bringing in $45 million from new investors including GV (formerly Google Ventures), Bill Gates and Foresite Capital, as well as all of the company’s previous investors...
January 7, 2020
Cerevance Appoints Clinical Development Veteran Dr. Aoife Brennan to Board of Directors
Dr. Brennan is currently president and chief executive officer of Synlogic, Inc. (Nasdaq:SYBX), a clinical stage biotechnology company applying synthetic biology to beneficial microbes to develop novel, living medicines.
December 17, 2019
Cerevance Enters Research Collaboration with Takeda to Advance New Treatments for Gastrointestinal Disorders
Cerevance has formed a multi-year research alliance with Takeda Pharmaceutical Company Limited (“Takeda”) to identify novel target proteins expressed in the central nervous system and to develop new therapies against them for certain GI disorders.
December 4, 2019
Cerevance Initiates Phase 2 Trial of CVN424 for Parkinson’s Disease
Cerevance, announced today the initiation of a Phase 2 clinical trial of CVN424, an oral, first-in-class compound that selectively modulates a novel, non-dopaminergic target selectively expressed in an important class of neurons in the striatum.
June 3, 2019
Cerevance Appoints CNS Drug Developer James Summers, Ph.D. as Scientific Advisor
Cerevance has appointed pharmaceutical industry veteran, James Summers, Ph.D., as a key scientific advisor to guide the company in its drug discovery and development efforts. Dr. Summers brings extensive experience in the discovery of...
April 30, 2019
Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424
Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has successfully completed its Phase 1 clinical trial of CVN424, the company’s first-in-class, orally-delivered compound in development for the treatment of Parkinson’s disease.
April 6, 2019
Cerevance Appoints Industry Veteran Roland Bürli, Ph.D. as Vice President of Drug Discovery
Roland Bürli, Ph.D. as Vice President of Drug Discovery brings expertise in preclinical drug discovery, specializing in medicinal and synthetic chemistry, with a proven track record from hit identification through lead optimization, having led efforts that discovered six pre-clinical candidate molecules, including a program now in Phase II.
March 5, 2019
Industry Central Nervous System Specialist Lee Dawson, Ph.D. Joins Cerevance as VP of Neuroscience
Dawson brings 25 years of career experience spearheading drug discovery and development across companies based in the United States, Japan and the United Kingdom. Most recently, he served as Vice President of CNS drug development at Astex Pharmaceuticals, where he established and developed their global neuroscience research strategy.
October 9, 2018
Cerevance Appoints Ted Hibben as Chief Business Officer
A twenty-year biotechnology industry veteran, Mr. Hibben has formed over $2 billion in platform and product-based R&D collaborations. Prior to joining Cerevance, Mr. Hibben served as Chief Business Officer at Catabasis where he led partnering activities.
September 25, 2018
Cerevance Announces First-in-Human Dosing of CVN424 for the Treatment of Parkinson’s Disease
Cerevance, a clinical-stage drug discovery and development company focused on brain diseases, today announced the start of dosing in a Phase I first-in-human clinical trial of CVN424, an oral compound being developed for symptomatic treatment of Parkinson’s disease.
February 11, 2018
Cerevance Kicks Off 2018 with Additional $10 Million of Infusions
Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has received an additional equity investment as well as a non-dilutive cash payment in the first six weeks of 2018 totaling more than $10 million.
November 27, 2017
Cerevance Appoints David H. Margolin, M.D., Ph.D., as Senior Vice President of Clinical and Translational Medicine
Prior to joining Cerevance, Dr. Margolin served in several leadership roles at Sanofi-Genzyme over a 14-year period. There, he leveraged his expertise in designing and leading translational medicine initiatives as well as clinical trials from phase 1 to phase 4 across various neurologic and rare disease indications...
October 24, 2017
Trailblazer in Molecular Genetics and Neuroscience, Jeremy Nathans, M.D., Ph.D., to Advise Cerevance
Dr. Nathans is Professor of Molecular Biology and Genetics, Neuroscience and Ophthalmology at the Johns Hopkins University School of Medicine in Baltimore, Maryland, where his research focuses on molecular mechanisms of visual system development, function, and disease. He is also an Investigator in the Howard Hughes Medical Institute.
October 17, 2017
Cerevance Licenses Human Brain Tissue Profiling Technology from The Rockefeller University
Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has signed an agreement with The Rockefeller University to license a novel technology for profiling specific cell populations in human brain tissue
October 12, 2017
Harvard’s Rudolph Tanzi, Ph.D., a Leader in Alzheimer’s Disease Genetics, Joins Cerevance’s Advisory Board
Cerevance, a drug discovery and development company focused on brain diseases, today announced that Rudolph Tanzi, Ph.D., has joined the company as a senior-level scientific advisor.
October 5, 2017
Stanford Neuroscientist, Robert Malenka, M.D., Ph.D., to Advise Cerevance
Cerevance, a drug discovery and development company, today announced that Robert Malenka, M.D., Ph.D., has joined the company as a senior-level scientific advisor. Dr. Malenka is the Pritzker Professor of Psychiatry and Behavioral Sciences at Stanford University.
May 3, 2017
Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia
The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance.
December 2, 2016
Cerevance Launched With New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases
- Takeda and Lightstone Ventures Participate in Series A Financing
- Former Takeda Cambridge UK employees, CNS programs moved to create turn-key discovery capabilities
Current
October 2, 2023
Cerevance to Present at the 36th European College of Neuropsychopharmacology Congress
September 5, 2023
Cerevance to Present During the 6th Annual LSX World Congress USA
August 31, 2023
22nd Society of Chemical Industry / Royal Society of Chemistry Medicinal Chemistry Symposium
July 10, 2023
Alzheimers Association International Conference
June 28, 2023
XVI European Meeting on Glial Cells in Health and Disease
June 26, 2023
Gordon Research Conference
May 16, 2023
Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)
May 9, 2023
Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development
May 8, 2023
2023 RBC Capital Markets Global Healthcare Conference
April 13, 2023
BNA International Festival of Neuroscience
April 10, 2023
Needham Healthcare Conference
March 27, 2023
Chief Medical Officer Summit 360˚
March 21, 2023
Two Medicinal Chemistry Conferences
March 20, 2023
AD/PD™ 2023 International Conference
March 7, 2023
Alzheimer’s Research UK Conference 2023
January 24, 2023
SVB Global Biopharma Conference
December 7, 2022
Cerevance to Present at the RBC Capital Markets Virtual Healthcare Private Company Conference
November 30, 2022
Biology and Therapeutics Conference
June 16, 2022
5th Annual LSX World Congress USA
June 8, 2022
2022 BIO International Convention